<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-311</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕГУЛЯТОРНЫЕ ВОПРОСЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REGULATORY ISSUES</subject></subj-group></article-categories><title-group><article-title>ОБЗОР, ХАРАКТЕРИСТИКА И АНАЛИЗ ПОСЛЕДНИХ ИЗМЕНЕНИЙ В ТРЕБОВАНИЯХ GMP</article-title><trans-title-group xml:lang="en"><trans-title>REVIEW, CHARACTERISTICS AND ANALYSIS OF THE LAST CHANGES IN THE GMP REQUIREMENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подпружников</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Podpruznikov</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестаков</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakov</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный фармацевтический университет</institution></aff><aff xml:lang="en"><institution>National University of Pharmacy</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФБУ «Государственный институт лекарственных средств и надлежащих практик»</institution></aff><aff xml:lang="en"><institution>The State Institution «State Institute of Drugs and Good Practices»</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>3</issue><fpage>202</fpage><lpage>218</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Подпружников Ю.В., Шестаков В.Н., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Подпружников Ю.В., Шестаков В.Н.</copyright-holder><copyright-holder xml:lang="en">Podpruznikov Y.V., Shestakov V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/311">https://www.pharmjournal.ru/jour/article/view/311</self-uri><abstract><p>Регуляторные требования в сфере промышленного производства постоянно повышаются, что находит отражение в правилах надлежащей производственной практики. В обзоре дана характеристика и проведен анализ изменений в правилах GMP, касающихся персонала, помещений и оборудования, производства, контроля качества, работы с рекламациями и отзывами, а так же новых редакций приложений по квалификации и валидации, подтверждению уполномоченным лицом соответствия серии продукции с целью ее выпуска. Для содействия интерпретации и внедрению этих новаций как в практик у предприятий-производителей, так и в перспективе в работ у регуляторных органов были проанализированы так же сопутствующие информационные источники. В обзоре представ лены рекомендации относительно приоритетов и точек приложения усилий по внедрению рассмотренных изменений.</p></abstract><trans-abstract xml:lang="en"><p>The regulatory requirements are constantly increasing in the medicines manufacturing sphere, which is reflected in the good manufacturing practice rules. The changes in the GMP regulations relating to personnel, premises and equipment, production, quality control, complaints, quality defects and product recalls, as well as a new version of qualification and validation annex and certification by a Qualified Person and batch release annex have been characterized and analyzed in a review. The related information sources have also been analyzed in order to facilitate the interpretation and implementation of these innovations in the practice of company-producers and, in the long term, the work of the regulatory authorities. The review provides recommendations on the priorities and points of application of efforts to implement the changes discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>надлежащая производственная практика</kwd><kwd>изменения в требованиях</kwd><kwd>валидация</kwd><kwd>перекрестная контаминация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Good Manufacturing Practice</kwd><kwd>changes in the requirements</kwd><kwd>validation</kwd><kwd>cross-contamination</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">The rules governing medicinal products in the European Union. Volume 4. Good manufacturing practice (GMP) Guidelines. URL: http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm (дата обращения 03.06.2016).</mixed-citation><mixed-citation xml:lang="en">The rules governing medicinal products in the European Union. Volume 4. Good manufacturing practice (GMP) Guidelines. URL: http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm (дата обращения 03.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Guide to good manufacturing practice for medicinal products. PIC/S GMP Guide. PE 009-12. URL: http://www.picscheme.org/publication.php (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">Guide to good manufacturing practice for medicinal products. PIC/S GMP Guide. PE 009-12. URL: http://www.picscheme.org/publication.php (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Правила надлежащей производственной практики Евразийского экономического союза (проект от 06.05.2015 г.). URL: http://www.eurasiancommission.org/ru/nae/news/Pages/07-05-2015-2.aspx (дата обращения 25.06.2016).</mixed-citation><mixed-citation xml:lang="en">Правила надлежащей производственной практики Евразийского экономического союза (проект от 06.05.2015 г.). URL: http://www.eurasiancommission.org/ru/nae/news/Pages/07-05-2015-2.aspx (дата обращения 25.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ю.В. Подпружников, А.А. Ишмухаметов, А.С. Нем ченко и др. Хрестоматия фармацевтического качества / Под ред. А.А. Ишмухаметова. - М.: РЕМЕДИУМ. 2015. 432 с.</mixed-citation><mixed-citation xml:lang="en">Ю.В. Подпружников, А.А. Ишмухаметов, А.С. Нем ченко и др. Хрестоматия фармацевтического качества / Под ред. А.А. Ишмухаметова. - М.: РЕМЕДИУМ. 2015. 432 с.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Правила надлежащей производственной практики. Утверждены приказом Министерства промышленности и торговли РФ от 14 июня 2013 г. № 916 (с изменениями).</mixed-citation><mixed-citation xml:lang="en">Правила надлежащей производственной практики. Утверждены приказом Министерства промышленности и торговли РФ от 14 июня 2013 г. № 916 (с изменениями).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Q10: Pharmaceutical Quality System. URL: http://www.ich.org/ (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">Q10: Pharmaceutical Quality System. URL: http://www.ich.org/ (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Quality Management Systems. Requirements: ISO 9001:2015. URL: http://www.iso.org (дата обращения 04.06.2016).</mixed-citation><mixed-citation xml:lang="en">Quality Management Systems. Requirements: ISO 9001:2015. URL: http://www.iso.org (дата обращения 04.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pharmaceutical Quality for the 21st Century A Risk- Based Approach Progress Report. Department of Health and Human Services U.S. Food and Drug Administration, May 2007. URL: http://www.fda.gov/ (дата обращения 07.06.2016).</mixed-citation><mixed-citation xml:lang="en">Pharmaceutical Quality for the 21st Century A Risk- Based Approach Progress Report. Department of Health and Human Services U.S. Food and Drug Administration, May 2007. URL: http://www.fda.gov/ (дата обращения 07.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Положение о лицензировании производства лекарственных средств. Утверждено постановлением Правительства РФ № 686 от 06 июля 2012 (в ред. от 15.04.2013).</mixed-citation><mixed-citation xml:lang="en">Положение о лицензировании производства лекарственных средств. Утверждено постановлением Правительства РФ № 686 от 06 июля 2012 (в ред. от 15.04.2013).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Code of Federal Regulations Title 21 - Food and Drugs. Chapter I - Food and Drug Administration. Department of Health and Human Services. Subchapter C - Drugs: general. PART 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Subpart C - Buildings and Facilities Sec. 211.42 Design and construction features. URL: https://www.access-data.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=211.42 (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">Code of Federal Regulations Title 21 - Food and Drugs. Chapter I - Food and Drug Administration. Department of Health and Human Services. Subchapter C - Drugs: general. PART 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Subpart C - Buildings and Facilities Sec. 211.42 Design and construction features. URL: https://www.access-data.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=211.42 (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">FDA Guidance for Industry «Non-Penicillin Beta- Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination». April 2013. URL: http://www.fda.gov/ (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">FDA Guidance for Industry «Non-Penicillin Beta- Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination». April 2013. URL: http://www.fda.gov/ (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. EMA/CHMP/ CVMP/ SWP/169430/2012. European Medicines Agency</mixed-citation><mixed-citation xml:lang="en">Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. EMA/CHMP/ CVMP/ SWP/169430/2012. European Medicines Agency</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Q9: Quality risk management. URL: http://www.ich.org/ (дата обращения 25.01.2016).</mixed-citation><mixed-citation xml:lang="en">Q9: Quality risk management. URL: http://www.ich.org/ (дата обращения 25.01.2016).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (Text with EEA relevance) (2015/C 95/02) // Official Journal of the European Union. 21.3.2015.</mixed-citation><mixed-citation xml:lang="en">Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (Text with EEA relevance) (2015/C 95/02) // Official Journal of the European Union. 21.3.2015.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная фармакопея Российской Федерации. ХIII изд.: в 3-х т. Т. 1 - М.: ФЭМБ, 2015. 1470 с. URL: http://femb.ru/feml (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">Государственная фармакопея Российской Федерации. ХIII изд.: в 3-х т. Т. 1 - М.: ФЭМБ, 2015. 1470 с. URL: http://femb.ru/feml (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">WHO good practices for pharmaceutical microbiology laboratories, Annex 2. WHO Technical Report Series, No. 961, 2011. URL: http://apps.who.int/ (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">WHO good practices for pharmaceutical microbiology laboratories, Annex 2. WHO Technical Report Series, No. 961, 2011. URL: http://apps.who.int/ (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;1226&gt; General Information / Verification of Compendial Procedures // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation><mixed-citation xml:lang="en">&lt;1226&gt; General Information / Verification of Compendial Procedures // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;5.3.N.2&gt; Валідація аналітичних методик і випробувань // Державна Фармакопея України: в 3 т. / Державне підприємство «Український науковий фармакопейний центр лікарських засобів», 2-е вид. - Харків: Український науковий фармакопейний центр лікарських засобів, 2015. Т. 2. С. 910-929.</mixed-citation><mixed-citation xml:lang="en">&lt;5.3.N.2&gt; Валідація аналітичних методик і випробувань // Державна Фармакопея України: в 3 т. / Державне підприємство «Український науковий фармакопейний центр лікарських засобів», 2-е вид. - Харків: Український науковий фармакопейний центр лікарських засобів, 2015. Т. 2. С. 910-929.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">L. Huber. Implementing New USP Chapters for Analytical Method Validation // LabСompliance. March 2010. URL: http://www.ivtnetwork.com/ (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">L. Huber. Implementing New USP Chapters for Analytical Method Validation // LabСompliance. March 2010. URL: http://www.ivtnetwork.com/ (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">General Information / Analytical instrument qualification // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation><mixed-citation xml:lang="en">General Information / Analytical instrument qualification // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Q8: Pharmaceutical development. URL: http://www.ich.org/ (дата обращения 25.01.2016).</mixed-citation><mixed-citation xml:lang="en">Q8: Pharmaceutical development. URL: http://www.ich.org/ (дата обращения 25.01.2016).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;1224&gt; General Information / Transfer of Analytical Procedures // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation><mixed-citation xml:lang="en">&lt;1224&gt; General Information / Transfer of Analytical Procedures // The United States Pharmacopeia. USP 37. - Rockville: The United States Pharmacopeial Convention.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Technical Report Series. No. 961. 2011. Annex 7. URL: http://www.who.int. (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Technical Report Series. No. 961. 2011. Annex 7. URL: http://www.who.int. (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">А.И. Гризодуб. Стандартизованные процедуры валидации методик контроля качества лекарственных средств. - Харьков: Украинский научный фармакопейный центр качества лекарственных средств, 2016. 396 с.</mixed-citation><mixed-citation xml:lang="en">А.И. Гризодуб. Стандартизованные процедуры валидации методик контроля качества лекарственных средств. - Харьков: Украинский научный фармакопейный центр качества лекарственных средств, 2016. 396 с.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Procedure for Handling Rapid Alerts Arising from Quality Defects. Date of adoption 31 January 2010. European Medicines Agency.</mixed-citation><mixed-citation xml:lang="en">Procedure for Handling Rapid Alerts Arising from Quality Defects. Date of adoption 31 January 2010. European Medicines Agency.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Procedure for handling rapid alerts and recalls arising from quality defects. Standard operating procedure PI 010-4. URL: http://www.picscheme.org/ publication.php (дата обращения 05.06.2016).</mixed-citation><mixed-citation xml:lang="en">Procedure for handling rapid alerts and recalls arising from quality defects. Standard operating procedure PI 010-4. URL: http://www.picscheme.org/ publication.php (дата обращения 05.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">GAMP Guide for Validation of Automated Systems, GAMP4. ISPE (GAMP Forum), 2001. URL: http://www.ispe.org (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">GAMP Guide for Validation of Automated Systems, GAMP4. ISPE (GAMP Forum), 2001. URL: http://www.ispe.org (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">FDA Guidance for Industry «Process Validation: General Principles and Practices». Rev.1. January 2011. URL: http://www.fda.gov/ (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">FDA Guidance for Industry «Process Validation: General Principles and Practices». Rev.1. January 2011. URL: http://www.fda.gov/ (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on process validation for finished products - information and data to be provided in regulatory submissions. EMA/CHMP/CVMP/QWP/ BWP/70278/ 2012-Rev1. European Medicines Agency. URL: http://ec.europa.eu/ (дата обращения 21.06.2016).</mixed-citation><mixed-citation xml:lang="en">Guideline on process validation for finished products - information and data to be provided in regulatory submissions. EMA/CHMP/CVMP/QWP/ BWP/70278/ 2012-Rev1. European Medicines Agency. URL: http://ec.europa.eu/ (дата обращения 21.06.2016).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ю.В. Подпружников. Сравнительный анализ критериев очистки в производстве лекарственных средств // Ремедиум. 2016. № 3. С. 46-51.</mixed-citation><mixed-citation xml:lang="en">Ю.В. Подпружников. Сравнительный анализ критериев очистки в производстве лекарственных средств // Ремедиум. 2016. № 3. С. 46-51.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Лікарські засоби. Належна виробнича практика. Настанова СТ-Н МОЗУ 42- 4.0:2015. - Київ: Міністерство охорони здоров’я України, 2015. 315 с</mixed-citation><mixed-citation xml:lang="en">Лікарські засоби. Належна виробнича практика. Настанова СТ-Н МОЗУ 42- 4.0:2015. - Київ: Міністерство охорони здоров’я України, 2015. 315 с</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
